Search

Your search keyword '"Schetelig, Johannes"' showing total 16 results
Start Over Author "Schetelig, Johannes" Journal leukemia
16 results on '"Schetelig, Johannes"'

1. How risky is a second allogeneic stem cell transplantation?

Author

Penack, Olaf, Abouqateb, Mouad, Peczynski, Christophe, Boreland, William, Kröger, Nicolaus, Zeiser, Robert, Ciceri, Fabio, Schroeder, Thomas, Dreger, Peter, Passweg, Jakob, Schetelig, Johannes, Stelljes, Matthias, Blau, Igor Wolfgang, Franke, Georg-Nikolaus, Riesner, Katarina, Schoemans, Hélène, Moiseev, Ivan, and Peric, Zinaida

Published
2024
Full Text
View/download PDF

2. Mutated IKZF1 is an independent marker of adverse risk in acute myeloid leukemia

Author

Eckardt, Jan-Niklas, Stasik, Sebastian, Röllig, Christoph, Petzold, Andreas, Sauer, Tim, Scholl, Sebastian, Hochhaus, Andreas, Crysandt, Martina, Brümmendorf, Tim H., Naumann, Ralph, Steffen, Björn, Kunzmann, Volker, Einsele, Hermann, Schaich, Markus, Burchert, Andreas, Neubauer, Andreas, Schäfer-Eckart, Kerstin, Schliemann, Christoph, Krause, Stefan W., Herbst, Regina, Hänel, Mathias, Hanoun, Maher, Kaiser, Ulrich, Kaufmann, Martin, Rácil, Zdenek, Mayer, Jiri, Oelschlägel, Uta, Berdel, Wolfgang E., Ehninger, Gerhard, Serve, Hubert, Müller-Tidow, Carsten, Platzbecker, Uwe, Baldus, Claudia D., Dahl, Andreas, Schetelig, Johannes, Bornhäuser, Martin, Middeke, Jan Moritz, and Thiede, Christian

Published
2023
Full Text
View/download PDF

3. Secondary-type mutations do not impact outcome in NPM1-mutated acute myeloid leukemia – implications for the European LeukemiaNet risk classification

Author

Eckardt, Jan-Niklas, Bill, Marius, Rausch, Christian, Metzeler, Klaus, Spiekermann, Karsten, Stasik, Sebastian, Sauer, Tim, Scholl, Sebastian, Hochhaus, Andreas, Crysandt, Martina, Brümmendorf, Tim H., Krug, Utz, Wörmann, Bernhard, Hiddemann, Wolfgang, Görlich, Dennis, Sauerland, Cristina, Steffen, Björn, Einsele, Hermann, Neubauer, Andreas, Burchert, Andreas, Schäfer-Eckart, Kerstin, Berdel, Wolfgang E., Schliemann, Christoph, Krause, Stefan W., Hänel, Mathias, Hanoun, Maher, Kaufmann, Martin, Fransecky, Lars, Braess, Jan, Ruhnke, Leo, Schetelig, Johannes, Middeke, Jan Moritz, Serve, Hubert, Baldus, Claudia D., Platzbecker, Uwe, Müller-Tidow, Carsten, Bornhäuser, Martin, Herold, Tobias, Thiede, Christian, and Röllig, Christoph

Published
2023
Full Text
View/download PDF

6. A multicenter prospective, randomized, placebo-controlled phase II/III trial for preemptive acute graft-versus-host disease therapy

Author

Weissinger, Eva M., Metzger, Jochen, Schleuning, Michael, Schmid, Christoph, Messinger, Diethelm, Beutel, Gernot, Wagner-Drouet, Eva-Maria, Schetelig, Johannes, Baurmann, Herrad, Rank, Andreas, Stolzl, Friedrich, Schäfer-Eckart, Kerstin, Westphal, Karin, Bethge, Wolfgang, von Harsdorf, S., Bunjes, Donald W., Heidenreich, Daniela, Klein, Stefan, Holler, Ernst, Kreipe, Hans H., Jonigk, Danny, Türüchanow, Irina, Raad, Julia, Papkalla, Armin, von der Leyen, Heiko, Hambach, Lothar, Hamwi, Iyas, Ehrlich, Steve, Krauter, Jurgen, Stadler, Michael, and Ganser, Arnold

Published
2021
Full Text
View/download PDF

7. The clinical mutatome of core binding factor leukemia

Author

Opatz, Sabrina, Bamopoulos, Stefanos A., Metzeler, Klaus H., Herold, Tobias, Ksienzyk, Bianka, Bräundl, Kathrin, Tschuri, Sebastian, Vosberg, Sebastian, Konstandin, Nikola P., Wang, Christine, Hartmann, Luise, Graf, Alexander, Krebs, Stefan, Blum, Helmut, Schneider, Stephanie, Thiede, Christian, Middeke, Jan Moritz, Stölzel, Friedrich, Röllig, Christoph, Schetelig, Johannes, Ehninger, Gerhard, Krämer, Alwin, Braess, Jan, Görlich, Dennis, Sauerland, Maria Cristina, Berdel, Wolfgang E., Wörmann, Bernhard J., Hiddemann, Wolfgang, Spiekermann, Karsten, Bohlander, Stefan K., and Greif, Philipp A.

Published
2020
Full Text
View/download PDF

8. Late treatment-related mortality versus competing causes of death after allogeneic transplantation for myelodysplastic syndromes and secondary acute myeloid leukemia

Author

Schetelig, Johannes, de Wreede, Liesbeth C., van Gelder, Michel, Koster, Linda, Finke, Jürgen, Niederwieser, Dietger, Beelen, Dietrich, Mufti, G. J., Platzbecker, Uwe, Ganser, Arnold, Heidenreich, Silke, Maertens, Johan, Socié, Gerard, Brecht, Arne, Stelljes, Matthias, Kobbe, Guido, Volin, Liisa, Nagler, Arnon, Vitek, Antonin, Luft, Thomas, Ljungman, Per, Yakoub-Agha, Ibrahim, Robin, Marie, and Kröger, Nicolaus

Published
2019
Full Text
View/download PDF

10. Mutated IKZF1is an independent marker of adverse risk in acute myeloid leukemia

Author

Eckardt, Jan-Niklas, Stasik, Sebastian, Röllig, Christoph, Petzold, Andreas, Sauer, Tim, Scholl, Sebastian, Hochhaus, Andreas, Crysandt, Martina, Brümmendorf, Tim H., Naumann, Ralph, Steffen, Björn, Kunzmann, Volker, Einsele, Hermann, Schaich, Markus, Burchert, Andreas, Neubauer, Andreas, Schäfer-Eckart, Kerstin, Schliemann, Christoph, Krause, Stefan W., Herbst, Regina, Hänel, Mathias, Hanoun, Maher, Kaiser, Ulrich, Kaufmann, Martin, Rácil, Zdenek, Mayer, Jiri, Oelschlägel, Uta, Berdel, Wolfgang E., Ehninger, Gerhard, Serve, Hubert, Müller-Tidow, Carsten, Platzbecker, Uwe, Baldus, Claudia D., Dahl, Andreas, Schetelig, Johannes, Bornhäuser, Martin, Middeke, Jan Moritz, and Thiede, Christian

Abstract

Genetic lesions of IKZF1are frequent events and well-established markers of adverse risk in acute lymphoblastic leukemia. However, their function in the pathophysiology and impact on patient outcome in acute myeloid leukemia (AML) remains elusive. In a multicenter cohort of 1606 newly diagnosed and intensively treated adult AML patients, we found IKZF1alterations in 45 cases with a mutational hotspot at N159S. AML with mutated IKZF1was associated with alterations in RUNX1, GATA2, KRAS, KIT, SF3B1, and ETV6, while alterations of NPM1, TET2, FLT3-ITD, and normal karyotypes were less frequent. The clinical phenotype of IKZF1-mutated AML was dominated by anemia and thrombocytopenia. In both univariable and multivariable analyses adjusting for age, de novo and secondary AML, and ELN2022 risk categories, we found mutated IKZF1to be an independent marker of adverse risk regarding complete remission rate, event-free, relapse-free, and overall survival. The deleterious effects of mutated IKZF1also prevailed in patients who underwent allogeneic hematopoietic stem cell transplantation (n= 519) in both univariable and multivariable models. These dismal outcomes are only partially explained by the hotspot mutation N159S. Our findings suggest a role for IKZF1mutation status in AML risk modeling.

Published
2023
Full Text
View/download PDF

11. Deep learning detects acute myeloid leukemia and predicts NPM1 mutation status from bone marrow smears

Author

Eckardt, Jan-Niklas, primary, Middeke, Jan Moritz, additional, Riechert, Sebastian, additional, Schmittmann, Tim, additional, Sulaiman, Anas Shekh, additional, Kramer, Michael, additional, Sockel, Katja, additional, Kroschinsky, Frank, additional, Schuler, Ulrich, additional, Schetelig, Johannes, additional, Röllig, Christoph, additional, Thiede, Christian, additional, Wendt, Karsten, additional, and Bornhäuser, Martin, additional

Published
2021
Full Text
View/download PDF

12. Secondary-type mutations do not impact outcome in NPM1-mutated acute myeloid leukemia – implications for the European leukemia net risk classification

Author

Eckardt, Jan-Niklas, Bill, Marius, Rausch, Christian, Metzeler, Klaus, Spiekermann, Karsten, Stasik, Sebastian, Sauer, Tim, Scholl, Sebastian, Hochhaus, Andreas, Crysandt, Martina, Brümmendorf, Tim H., Krug, Utz, Wörmann, Bernhard, Hiddemann, Wolfgang, Görlich, Dennis, Sauerland, Cristina, Steffen, Björn, Einsele, Hermann, Neubauer, Andreas, Burchert, Andreas, Schäfer-Eckart, Kerstin, Berdel, Wolfgang E., Schliemann, Christoph, Krause, Stefan W., Hänel, Mathias, Hanoun, Maher, Kaufmann, Martin, Fransecky, Lars, Braess, Jan, Ruhnke, Leo, Schetelig, Johannes, Middeke, Jan Moritz, Serve, Hubert, Baldus, Claudia D., Platzbecker, Uwe, Müller-Tidow, Carsten, Bornhäuser, Martin, Herold, Tobias, Thiede, Christian, and Röllig, Christoph

Published
2023
Full Text
View/download PDF

13. A multicenter prospective, randomized, placebo-controlled phase II/III trial for preemptive acute graft-versus-host disease therapy

Author

Weissinger, Eva M., primary, Metzger, Jochen, additional, Schleuning, Michael, additional, Schmid, Christoph, additional, Messinger, Diethelm, additional, Beutel, Gernot, additional, Wagner-Drouet, Eva-Maria, additional, Schetelig, Johannes, additional, Baurmann, Herrad, additional, Rank, Andreas, additional, Stolzl, Friedrich, additional, Schäfer-Eckart, Kerstin, additional, Westphal, Karin, additional, Bethge, Wolfgang, additional, von Harsdorf, S., additional, Bunjes, Donald W., additional, Heidenreich, Daniela, additional, Klein, Stefan, additional, Holler, Ernst, additional, Kreipe, Hans H., additional, Jonigk, Danny, additional, Türüchanow, Irina, additional, Raad, Julia, additional, Papkalla, Armin, additional, von der Leyen, Heiko, additional, Hambach, Lothar, additional, Hamwi, Iyas, additional, Ehrlich, Steve, additional, Krauter, Jurgen, additional, Stadler, Michael, additional, and Ganser, Arnold, additional

Published
2020
Full Text
View/download PDF

14. Late treatment-related mortality versus competing causes of death after allogeneic transplantation for myelodysplastic syndromes and secondary acute myeloid leukemia

Author

Schetelig, Johannes, primary, de Wreede, Liesbeth C., additional, van Gelder, Michel, additional, Koster, Linda, additional, Finke, Jürgen, additional, Niederwieser, Dietger, additional, Beelen, Dietrich, additional, Mufti, G. J., additional, Platzbecker, Uwe, additional, Ganser, Arnold, additional, Heidenreich, Silke, additional, Maertens, Johan, additional, Socié, Gerard, additional, Brecht, Arne, additional, Stelljes, Matthias, additional, Kobbe, Guido, additional, Volin, Liisa, additional, Nagler, Arnon, additional, Vitek, Antonin, additional, Luft, Thomas, additional, Ljungman, Per, additional, Yakoub-Agha, Ibrahim, additional, Robin, Marie, additional, and Kröger, Nicolaus, additional

Published
2018
Full Text
View/download PDF

15. Sorafenib or placebo in patients with newly diagnosed acute myeloid leukaemia: long-term follow-up of the randomized controlled SORAML trial

Author

Röllig, Christoph, Serve, Hubert, Noppeney, Richard, Hanoun, Maher, Krug, Utz, Baldus, Claudia D., Brandts, Christian H., Kunzmann, Volker, Einsele, Hermann, Krämer, Alwin, Müller-Tidow, Carsten, Schäfer-Eckart, Kerstin, Neubauer, Andreas, Burchert, Andreas, Giagounidis, Aristoteles, Krause, Stefan W., Mackensen, Andreas, Aulitzky, Walter, Herbst, Regina, Hänel, Mathias, Frickhofen, Norbert, Kullmer, Johannes, Kaiser, Ulrich, Kiani, Alexander, Link, Hartmut, Geer, Thomas, Reichle, Albrecht, Junghanß, Christian, Repp, Roland, Meinhardt, Achim, Dürk, Heinz, Klut, Ina-Maria, Bornhäuser, Martin, Schaich, Markus, Parmentier, Stefani, Görner, Martin, Thiede, Christian, von Bonin, Malte, Platzbecker, Uwe, Schetelig, Johannes, Kramer, Michael, Berdel, Wolfgang E., and Ehninger, Gerhard

Abstract

Early results of the randomized placebo-controlled SORAML trial showed that, in patients with newly diagnosed acute myeloid leukaemia (AML), sorafenib led to a significant improvement in event-free (EFS) and relapse-free survival (RFS). In order to describe second-line treatments and their implications on overall survival (OS), we performed a study after a median follow-up time of 78 months. Newly diagnosed fit AML patients aged ≤60 years received sorafenib (n= 134) or placebo (n= 133) in addition to standard chemotherapy and as maintenance treatment. The 5-year EFS was 41 versus 27% (HR 0.68; p= 0.011) and 5-year RFS was 53 versus 36% (HR 0.64; p= 0.035). Allogeneic stem cell transplantation (allo SCT) was performed in 88% of the relapsed patients. Four years after salvage allo SCT, the cumulative incidence of relapse was 54 versus 35%, and OS was 32 versus 50%. The 5-year OS from randomization in all study patients was 61 versus 53% (HR 0.82; p= 0.282). In conclusion, the addition of sorafenib to chemotherapy led to a significant prolongation of EFS and RFS. Although the OS benefit did not reach statistical significance, these results confirm the antileukaemic activity of sorafenib.

Published
2021
Full Text
View/download PDF

16. Deep learning detects acute myeloid leukemia and predicts NPM1mutation status from bone marrow smears

Author

Eckardt, Jan-Niklas, Middeke, Jan Moritz, Riechert, Sebastian, Schmittmann, Tim, Sulaiman, Anas Shekh, Kramer, Michael, Sockel, Katja, Kroschinsky, Frank, Schuler, Ulrich, Schetelig, Johannes, Röllig, Christoph, Thiede, Christian, Wendt, Karsten, and Bornhäuser, Martin

Abstract

The evaluation of bone marrow morphology by experienced hematopathologists is essential in the diagnosis of acute myeloid leukemia (AML); however, it suffers from a lack of standardization and inter-observer variability. Deep learning (DL) can process medical image data and provides data-driven class predictions. Here, we apply a multi-step DL approach to automatically segment cells from bone marrow images, distinguish between AML samples and healthy controls with an area under the receiver operating characteristic (AUROC) of 0.9699, and predict the mutation status of Nucleophosmin 1 (NPM1)—one of the most common mutations in AML—with an AUROC of 0.92 using only image data from bone marrow smears. Utilizing occlusion sensitivity maps, we observed so far unreported morphologic cell features such as a pattern of condensed chromatin and perinuclear lightening zones in myeloblasts of NPM1-mutated AML and prominent nucleoli in wild-type NPM1AML enabling the DL model to provide accurate class predictions.

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results